| Julie Light, PT | |
|
1200 Airport Heights Dr Ste 170, Anchorage, AK 99508-2986 | |
| (907) 562-2118 | |
| (907) 562-2128 |
| Full Name | Julie Light |
|---|---|
| Gender | Female |
| Speciality | Physical Therapy |
| Experience | 3 Years |
| Location | 1200 Airport Heights Dr Ste 170, Anchorage, Alaska |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245990597 | NPI | - | NPPES |
| 2019019041 | Other | MO | RN LICENSE |
| 2021019717 | Other | MO | PT LICENSE |
| 7274 | Other | ID | PT LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | 7274 (Idaho) | Secondary |
| 225100000X | Physical Therapist | 2021019717 (Missouri) | Primary |
| Provider Name | Nor-alaska Physical Therapy, Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1326586348 PECOS PAC ID: 7214211036 Enrollment ID: O20170222002922 |
News Archive
CANCER RESEARCH UK and Cancer Research Technology - the charity's development and commercialisation arm - have reached a collaboration agreement with immatics Biotechnologies to trial their new treatment vaccine, IMA950, for glioblastoma multiforme (GMB), one of the most common forms of brain cancer.
State health news coverage includes political vandalism in Colorado, health-related bills in Maine, Medicaid cuts in Maryland and a dismissed medical malpractice lawsuit in Florida.
Because of the very high costs in developing drugs for rare genetic diseases, and the low return on investment, the pharmaceutical industry has rarely developed specific treatments for many of these diseases.
Exelixis, Inc. announced the presentation of preclinical data that provide insight into the mechanism of action of its lead compound, cabozantinib, with respect to its activity against prostate cancer tumors that have metastasized to the bone.
› Verified 4 days ago
| Provider Name | Light Physical Therapy Llc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1205545498 PECOS PAC ID: 4688043334 Enrollment ID: O20221220000839 |
News Archive
CANCER RESEARCH UK and Cancer Research Technology - the charity's development and commercialisation arm - have reached a collaboration agreement with immatics Biotechnologies to trial their new treatment vaccine, IMA950, for glioblastoma multiforme (GMB), one of the most common forms of brain cancer.
State health news coverage includes political vandalism in Colorado, health-related bills in Maine, Medicaid cuts in Maryland and a dismissed medical malpractice lawsuit in Florida.
Because of the very high costs in developing drugs for rare genetic diseases, and the low return on investment, the pharmaceutical industry has rarely developed specific treatments for many of these diseases.
Exelixis, Inc. announced the presentation of preclinical data that provide insight into the mechanism of action of its lead compound, cabozantinib, with respect to its activity against prostate cancer tumors that have metastasized to the bone.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Julie Light, PT 1200 Airport Heights Dr Ste 170, Anchorage, AK 99508-2986 Ph: (907) 562-2118 | Julie Light, PT 1200 Airport Heights Dr Ste 170, Anchorage, AK 99508-2986 Ph: (907) 562-2118 |
News Archive
CANCER RESEARCH UK and Cancer Research Technology - the charity's development and commercialisation arm - have reached a collaboration agreement with immatics Biotechnologies to trial their new treatment vaccine, IMA950, for glioblastoma multiforme (GMB), one of the most common forms of brain cancer.
State health news coverage includes political vandalism in Colorado, health-related bills in Maine, Medicaid cuts in Maryland and a dismissed medical malpractice lawsuit in Florida.
Because of the very high costs in developing drugs for rare genetic diseases, and the low return on investment, the pharmaceutical industry has rarely developed specific treatments for many of these diseases.
Exelixis, Inc. announced the presentation of preclinical data that provide insight into the mechanism of action of its lead compound, cabozantinib, with respect to its activity against prostate cancer tumors that have metastasized to the bone.
› Verified 4 days ago
Katrina F Johnson, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 4315 Diplomacy Dr, Anchorage, AK 99508 Phone: 907-563-2662 | |
Jessie Lief, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 4031 Winchester Loop, Anchorage, AK 99507 Phone: 907-244-8048 | |
Zoe Anneliese Morris Nelson, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1917 Abbott Rd Ste 200, Anchorage, AK 99507 Phone: 907-279-4266 | |
Normajean Farr, PT Physical Therapist Medicare: Medicare Enrolled Practice Location: 2221 E Northern Lights Blvd, Suite 106, Anchorage, AK 99508 Phone: 907-677-5605 | |
Mary Beth Nearing, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 602 W 42nd Ave, Anchorage, AK 99503 Phone: 907-360-9448 Fax: 907-346-1470 | |
Kids Are People Too Llc Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 6311 Debarr Rd, Suite J, Anchorage, AK 99504 Phone: 907-830-3592 Fax: 907-338-4691 | |
Ms. Catherine A Coward, MSPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 9500 Independence Dr, Ste 900, Anchorage, AK 99507 Phone: 907-522-1341 Fax: 907-522-1343 |